Eli Lilly and Company announced that Anat Ashkenazi has resigned as CFO to pursue a career opportunity outside of the pharmaceutical industry. Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly’s Executive Committee through July 2024. An internal and external search for her successor is actively underway.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s (NYSE:LLY) Tirzepatide Gets UK Endorsement for Obesity
- Eli Lilly presents updated data from Phase 1/2 study of Olomorasib
- ZTS, SYK, LLY: Which Healthcare Stock Is the Best Buy?
- Structure Therapeutics (NASDAQ:GPCR): Analysts See 130% Upside in This GLP-1 Stock
- FDA grants Lilly’s Retevmo accelerated approval for thyroid cancer